Showing results (461-470 of 831) with videos related to
Sort By:
Pageof 84
The Lancet. Haematology|October 6, 2015
Ponatinib as first-line treatment for patients with chronic myeloid leukaemia in chronic phase: a phase 2 studyPreetesh Jain, Hagop Kantarjian, Elias Jabbour, et al.Cancer Chemotherapy and Pharmacology|March 1, 2015
The effect of food on the pharmacokinetics of oral ibrutinib in healthy participants and patients with chronic lymphocytic leukemiaJan de Jong, Juthamas Sukbuntherng, Donna Skee, et al.European Journal of Haematology|November 7, 2023
HyperCVAD versus pegaspargase-containing regimens for Hispanic adults with newly diagnosed B-cell acute lymphoblastic leukemiaBenjamin J Lee, Shawn P Griffin, Jean Doh, et al.Journal of Immunology (Baltimore, Md. : 1950)|January 13, 2017
Ibrutinib Therapy Increases T Cell Repertoire Diversity in Patients with Chronic Lymphocytic LeukemiaQingsong Yin, Mariela Sivina, Harlan Robins, et al.Cancer|April 15, 2005
Survival benefit with imatinib mesylate therapy in patients with accelerated-phase chronic myelogenous leukemia--comparison with historic experienceHagop Kantarjian, Moshe Talpaz, Susan O'Brien, et al.Cancer Biomarkers : Section a of Disease Markers|February 27, 2009
Detection of nucleophosmin gene mutations in plasma from patients with acute myeloid leukemia: clinical significance and implicationsWanlong Ma, Hagop Kantarjian, Xi Zhang, et al.Haematologica|July 2, 2013
Assessment at 6 months may be warranted for patients with chronic myeloid leukemia with no major cytogenetic response at 3 monthsAziz Nazha, Hagop Kantarjian, Preetesh Jain, et al.Blood|March 15, 2003
Result of high-dose imatinib mesylate in patients with Philadelphia chromosome-positive chronic myeloid leukemia after failure of interferon-alphaJorge Cortes, Francis Giles, Susan O'Brien, et al.Blood|July 14, 2011
Frontline chemoimmunotherapy with fludarabine, cyclophosphamide, alemtuzumab, and rituximab for high-risk chronic lymphocytic leukemiaSameer A Parikh, Michael J Keating, Susan O'Brien, et al.Cancer|May 16, 2006
Outcomes in patients with splenic marginal zone lymphoma and marginal zone lymphoma treated with rituximab with or without chemotherapy or chemotherapy aloneApostolia M Tsimberidou, Daniel Catovsky, Ellen Schlette, et al.Pageof 84